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Expression of myeloid or T cell lymphoid on prescursor B cell lymphoblastic leukemia (presB cell ALL), which is referred to as aberrant expression, 
is quite a common phenomenon. There is an ongoing 
controversy regarding its clinical significance. Although 
the EGIL (European Group for the Immunological 
Classification of Leukemias) had worked on a scors
ing system to objectively classify this phenomenon, the 
prognostic significance of different markers is not well 
understood. The presence of the BCR/ABL rearranges
ment, the reciprocal t(9;22) (q34;q11) translocation, 
confers the worst prognosis in adult and pediatric pres
B cell ALL. 
CD66c (CEACAM6, previously called nonspecific 
crosssreacting antigen, NCA 90/50 and KORsSA3544 
antigen) is a glycoprotein with a molecular weight of 
90s110 KDa which is anchored to the membrane via 
glycosaylsphosphatidylinositol (GPI). It is highly exs
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BACKGROUnD: expression of myeloid or t cell lymphoid in precursor b cell acute lymphoblastic leukemia (pre-
b cell all), which is referred to as aberrant expression, is quite a common phenomenon. cd66c is a myeloid 
marker which has aberrant expression in pre-b cell all, with strong correlation with non-random genetic changes 
(bcr/abl rearrangement). another leukemia associated marker (cd25) is frequently expressed in pre-b cell all. 
the frequency of cd25–expressing lymphoblasts has been found to be significantly higher in bcr/abl-positive 
vs. bcr/abl-negative patients.
METHODS: in a cohort of 103 patients diagnosed with pre-b cell all or biphenotypic leukemia and studied for 
expression of cd66c and cd25 at presentation, we evaluated the frequency of expression of either or both in 
bcr/abl positive cases. 
RESULTS: Surface cd66c was expressed by 70 cases (68%) and cd25 was expressed by 33 cases (32%) while 
both were expressed together on 29 cases (28%). bcr/abl was positive in 18/103 patients. all bcr/abl positive 
cases were positive for surface cd66c and cd25. 
COnCLUSIOn: positivity for both leukemia-associated antigens cd66c and cd25 in combination can predict 
the presence of bcr/abl rearrangement in pre-b cell all. While this finding does not replace the detection of 
bcr/abl abnormality by cytogenetic or molecular techniques, it does provide an early and handy tool for predic-
tion and management of high-risk cases of pre-b cell all, especially in centers with limited laboratory facilities.
pressed on the surface (and intracellularly) of normal 
granulocytes.1,2 Although a myeloid antigen it frequents
ly has aberrant expression in presB cell ALL. CD66c 
expression was consistently found on cases of presB cell 
ALL3s5 with strong correlation with nonrandom genetic 
changes, including BCR/ABL positivity6s8 and TEL/
AML1 negativity.9 However, the correlation of express
sion of CD66c and positivity for BCR/ABL mutation 
was not robust in many studies. 
CD25 (interleukins2 a chain receptor [IL2R]) is 
defined by its reactivity with CD25srelated monoclos
nal antibodies. It is not present on the surface of resting 
Ts or Bslymphocytes, but is rapidly expressed following 
activation.10,11 CD25 is expressed in different lymphoid 
malignancies including acute lymphoblastic leukemia;12 
however, the clinical significance of ILs2 receptor exs
pression on blast cells has rarely been addressed.13 
In an interim analysis of the association between 
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antigen profile and BCR/ABL rearrangement, the fres
quency of CD25 expressing lymphoblasts was found 
to be significantly higher in BCR/ABLspositive than 
BCR/ABLsnegative patients.12 This suggested that 
CD25 may serve as a surrogate marker for the presence 
of this genetic abnormality in ALL blast cells. Increased 
expression of the multidrug resistance gene (MDR1) 
was also found in CD25spositive leukemia compared 
with CD25snegative leukemia.14 We examined the exs
pression of CD66c and CD25 in adult and childhood 
acute lymphoblastic leukemia and the ability to use that 
expression for prediction of the presence of BCR/ABL 
abnormality.
METHODS
A cohort of 103 patients diagnosed with precursor B 
cell acute lymphoblastic or biphenotypic leukemia at 
our institute between February 2003 and September 
2006 were studied for expression of CD66c and CD25 
at presentation. The diagnosis was based on an initial 
morphological and cytochemical evaluation that was 
confirmed by extensive immunophenotyping, cytoges
netics and special molecular studies.
Immunophenotyping: Bone marrow aspirates were 
obtained and collected using a sodium heparin tube and 
delivered immediately to the flowcytometry section. An 
aliquot from the aspirate was washed twice using phoss
phate buffer saline (PBS) buffer with 1% bovine serum 
albumin (BSA) and 0.1% sodium azide (NaN3). After 
the last wash the aspirate was filtered and the count ads
justed to 0.5s1×109/L of which a 100 uL aliquot was 
placed in each tube and incubated with the appropriate 
combination of monoclonal antibodies for 15s20 mins
utes in the dark (room temperature). Once the incubas
tion period was finished the red cells were lysed using a 
Coulter Lysing Kit (Immunolyse) followed by a single 
washing step. The cells were ressuspended in 0.5 mL 
of 1% paraformaldehyde and stored in the refrigerator 
until time of analysis. For staining of the cytoplasmic 
antigens the IntrasPrep Permeabilization Reagent kit 
from Beckman Coulter was used, strictly following the 
recommendations of the manufacturer. All cases were 
subjected to the whole blood lysing method upon stains
ing with monoclonal antibodies directly conjugated to 
fluorochromes. Antigen expression was analyzed on 
a fluorescent activated cell sorter (FACS) (Calibur, 
Becton Dickinson, San Jose, California, USA) using 
4s and 3scolor staining using the following combinas
tions of fluorochromesconjugated monoclonal antibods
ies fluorescein isothiocyanate (FITC), phycoerthrin 
(PE), peridin clor ophyll protein (PerCP) and allophys
cocyanin (APC) directed against surface antigens in 
combinations as: CD14/CD11c/CD45, CD3/CD8/
CD45/CD4, CD10/CD20/CD45/CD19, CD61/
CD33/CD45/CD34, CD7/CD13/CD45/ Human 
Leukocyte Antigen (HLA)sDR, KAPPA/LAMBDA/
CD45/CD19, CD9/CD2/CD45/CD22, CD64/
CD117/CD45/CD56, CD65/NG2/CD45/CD19, 
CD58/CD66C/CD45/CD19, CD25/CD38/CD45. 
In addition, the expression of myeloperoxidase enzyme 
(MPO), terminal deoxy transferase enzyme (TdT), 
CD3, immunoglobulin M (IgM) and CD79a was also 
performed at the cytoplasmic level.
Data acquisition was performed using Cell Quest 
software (Becton Dickinson) and a minimum of 10 000 
events/tube was acquired. Instruments were daily calis
brated using CALIBRITE beads (Becton Dickinson) 
and a two level control for CD3/CD8/CD45/CD4, 
and CD3/CD16+56/CD45/CD19 was run daily 
to ensure consistency in the functions of the instrus
ments. Data analysis was performed using Cell Quest 
software and the blast cells were gated using CD45 vs. 
side scatter (SSC) technique. Samples were considered 
positive when ≥20 % of the viable cells stained with a 
particular antibody in excess of the negative control. 
The criteria for diagnosis of biphenotypic acute leukes
mia (BAL) were based on the EGIL scoring system.15 
Hyperdiploidy was assessed using DNA index flow cys
tometric measurement as described previously.16 
Chromosome Analysis: Chromosome analysis from 
bone marrow aspirate cells was performed accords
ing to our standard laboratory techniques. Briefly, 18 
hour and/or 24 hour cultures were set up in RPMI 
1640 culture medium (catalog number 59s202s77, 
JRH Biosciences, USA), supplemented with 20% fes
tal bovine serum (Cat # 12s106s77P, JRH Biosciences, 
USA), 12% GCT conditioned medium (Cat # 50s
0815, IGEN, USA), 2% LsGlutamine (200mM, Cat # 
59s202s77, JRH Biosciences, USA), 5000ug/mL gens
tamicin (Cat # G1522, Sigma, USA). Cultures were ins
cubated at 37ºC in 5% CO2 environment and harvests
ed after a short treatment with ethidium bromide (1h, 
5 ug/mL), colcemid (1h, 10 ng/mL, Cat # 9311, Irvine 
Scientific, USA), cancer hypotonic solution (1h) and a 
3:1 methanol acetic acid mixture. At least twenty GTG 
banded metaphases were used for karyotype analysis. 
Definition of a clone and karyotype designation was acs
cording to ISCN (1995).
Molecular analysis: Red cells of blood and bone mars
row specimens, collected in EDTA, were lysed and 
the nucleated cell pellet transferred to DNAZOL and 
TRIZOL. A guanidinumsbased solution and nucleic 
acid were separated by selective precipitation using isos
propanolsdigested proteins. Isolated nucleic acid was 
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evaluated for quality and quantity using agarose gel 
electrophoresis as well as spectrophotometer readings 
at 260 and 280 nm. For the detection of BCR/ABL 
P210 (mRNA), total RNA was reverse transcribed. 
The generated cDNA was amplified with a forward 
primer located in the BCR exon b2 to combine with the 
reverse primer in the ABL exon a4. The fluorescent hys
bridization probe pair used is located in the ABL exon 
a3. The location of primers and hybridization probes 
also allowed the amplification and detection of the 
b2a3 and b3a3 fusion transcripts. The amount of fluos
rescence resulting from the two probes is proportional 
to the amount of PCR product. For BCR/ABL P190, 
a nested PCR was used to amplify BCRsABL cDNA 
after reverse transcription of mRNA.
For fluorescent in situ hypridization (FISH) analys
sis, LSI BCR/ABL ES, Cat. # 32s191022; LSI Mix 
Lineage Leukemia (MLL) gene dual color probe, Cat.# 
32s190083 and X and Y probes Cat. # (AbbotsVysis 
Inc., Downers Grove, Il, USA) were used to detect 
BCR/ABL, MLL rearrangement and loss of sex chros
mosomes in the interphase cells. Pres and posts hys
bridization procedure was performed according to the 
manufacturer.
Statistical analysis: Data were entered into the stas
tistical software SAS (SAS Institute Inc., version 9.1). 
The mean, median, range, frequency, standard devias
tion and percentage were used as descriptive statistics. 
McNemar’s Test was used to measure the agreement 
between the flowcytometric CD66c and CD25 marks
ers and cytogenetic/molecular tests for prediction of 
BCR/ABL abnormality. The sensitivity, the true pros
portion of positive results, and the specificity, the true 
proportion of negative results, were estimated. 
RESULTS
Of the 103 patients there were 38 adults (>14 years of 
age) and 65 children with an age range of 2 to 63 years 
and a median age of 13.3 years. There were 61 males 
and 42 females with M:F ratio of 1.5:1. The mean 
WBC count on presentation was 27.34±49.68×109/
L, hemoglobin 89.46±18.12 g/L, platelet 66.33±75.41 
109/L and blasts 41.03±31.94%. 
Immunophenotype: The majority of patients (96, 
93%) had precursor B cell acute lymphoblastic leus
kemia (presB ALL) and 7 patients were diagnosed as 
acute biphenotypic leukemia based on the EGIL scors
ing system. Almost all the patients expressed the B cell 
antigens CD19 and CD22. CD58 was overexpressed in 
92 (89%) while CD38 was expressed in 95 (92%) pas
tients. The myeloid antigens CD13, CD33, and CD15 
were expressed in 41(40%), 37(36%) and 18 (18.5%) 
patients, respectively while CD117 was positive in 2 of 
68 studied patients. Surface CD66c was expressed on 
70 (68%) of the cases;11 of the 33 negative for sCD66c 
were studied for cytoplasmic CD66c and were negative. 
CD25 was expressed by 33 (32%) of the patients and 
both CD66c and CD25 were expressed together on 29 
(28%). DNA polidy was examined in 67 newly diags
nosed patients. Hyperdiploidy >1.16s1.6 was found in 
20 (30%) of the patients; none of them were positive 
for Ph chromosome and all were positive for CD66c.
Cytogenetic and molecular studies: Cytogenetic 
analysis was successful in 71/103 patients. All nons
successful cases except one were studied by molecular 
polymerase chain reaction (PCR) technique for BCR/
ABL transcripts. Normal karyotype was found in 41 
(58%) of the analyzed cases. BCR/ABL was positive 
in 18/103 patients, Ph were detected cytogenetically in 
12 patients and in another 6 patients by FISH and mos
lecular techniques. All cases with BCR/ABL positivity 
were positive for sCD66c and CD25 with a sensitivity 
of 100% and specificity of 87%. Of 49 patients studs
ied for MLL gene by FISH, 5 (10%) were positive and 
none showed expression of CD66c/CD25 (Table 1).
DISCUSSIOn
There was great improvement in the outcome of the 
treatment of adult and childhood presB cell ALL with 
first complete remission reaching 80% to 90% by varis
ous protocols;17s19 however, failure to respond and early 
relapses remain as challenges for treating physicians. 
Table	1.	Correlations between genetic abnormalities and immunophenotyping expression.
Genetic	abnormality No.	patients CD25+ CD66c+ CD25+/CD66c+ CD13+/CD33+
ph. positive 18 18 18 18 12
ph. negative 85 15 52 11 14
mll  positive 5 0 2 0 0
mll negative 44 13 26 9 10
Hyperdiploidy 20 5 20 4 1
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The initial risk stratification of acute leukemia is an 
important step for selection of appropriate treatment. 
Most of the factors used in risk stratification are labos
ratory based and some are very specialized and not afs
fordable by every treating center. Since patients with 
BCRsABL positive presB cell ALL have an extremely 
poor prognosis,19 it is very important to predict the 
presence of this abnormality upfront so patients will 
receive the appropriate highsrisk treatment protocol. 
A BCRsABL abnormality can be detected by different 
techniques from standard karyotyping to various mos
lecular techniques. Nakazawa et al had demonstrated 
earlier positivity of CD66c in all studied cases of Ph+ 
acute lymphoblastic leukemia.6 Another study demons
strated the presence of BCR/ABL abnormality in 7 of 
8 patients with presB cell ALL positive for CD66c.8 In 
the same study, none of the positive cases for CD66c 
had the MLL abnormality while we had only 2 posis
tive cases out of 49 studied cases. CD66c as a myeloid 
marker is frequently coexpressed in presB cell ALL. 
Kalina et al showed that CD66c is expressed in 43% 
of patients,8 while we had detected CD66c in 68% of 
patients. In both studies it is the most frequently exs
pressed myeloid antigen when compared with other 
myeloid antigens. Both studies showed that when 
CD66c is negative at the surface it is not detected at 
the cytoplasmic level. Another observation was that the 
frequency of CD25 expressing lymphoblasts was found 
to be significantly higher in BCR/ABLspositive than 
BCR/ABLsnegative cases of presB cell ALL.12,13 In our 
study we tried to improve the detection rate and both 
specificity and sensitivity by combining both CD66c 
and CD25 for detection of BCR/ABL abnormality. 
This study did not address the prognostic significance 
of this finding, but we are planning to find the correlas
tions and particularly for the 11 cases with BCR/ABL 
negativity. We believe the value of this finding is not 
to replace the detection of BCR/ABL abnormality by 
cytogenetic or molecular techniques, but it will provide 
an early and handy tool for prediction and management 
of highsrisk cases of presB ALL especially in centers 
with limited laboratory facilities.
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